Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H14N2O |
Molecular Weight | 250.2952 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC2=CC=CC=C2C(=O)N1C3=C(C)C=CC=C3
InChI
InChIKey=JEYCTXHKTXCGPB-UHFFFAOYSA-N
InChI=1S/C16H14N2O/c1-11-7-3-6-10-15(11)18-12(2)17-14-9-5-4-8-13(14)16(18)19/h3-10H,1-2H3
Molecular Formula | C16H14N2O |
Molecular Weight | 250.2952 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/illicit/quaaludes.htmlCurator's Comment: description was created based on several sources, including:
http://www.encyclopedia.com/science/applied-and-social-sciences-magazines/methaqualone | https://www.ncbi.nlm.nih.gov/pubmed/26056160 | https://addictionlibrary.org/prescription/mandrax-uses-symptoms-signs-and-addiction-treatment.html
Sources: https://www.drugs.com/illicit/quaaludes.html
Curator's Comment: description was created based on several sources, including:
http://www.encyclopedia.com/science/applied-and-social-sciences-magazines/methaqualone | https://www.ncbi.nlm.nih.gov/pubmed/26056160 | https://addictionlibrary.org/prescription/mandrax-uses-symptoms-signs-and-addiction-treatment.html
Methaqualone is a depressant that modulates the activity of the GABA receptors in the brain and nervous system. It promotes relaxation, sleepiness and sometimes a feeling of euphoria. It causes a drop in blood pressure and slows the pulse rate. These properties are the reason why it was initially thought to be a useful sedative and anxiolytic. Common side effects of Methaqualone include dizziness, nausea, vomiting, diarrhea, abdominal cramps, fatigue, itching, rashes, sweating, dry mouth, tingling sensation in arms and legs, seizures and its depressant effects include reduced heart rate and respiration. The drug became banned in many countries and was withdrawn from many markets in the early 1980s.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GABA A receptor alpha-6/beta-1/delta Sources: https://www.ncbi.nlm.nih.gov/pubmed/26056160 |
4.0 null [pEC50] | ||
Target ID: GABA A receptor alpha-4/beta-2/delta Sources: https://www.ncbi.nlm.nih.gov/pubmed/26056160 |
4.17 null [pEC50] | ||
Target ID: GABA A receptor alpha-4/beta-3/delta Sources: https://www.ncbi.nlm.nih.gov/pubmed/26056160 |
3.91 null [pEC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Quaalude Approved UseMethaqualone is indicated for the treatment of anxiety and sleep disorders. Launch Date1954 |
|||
Primary | Quaalude Approved UseMethaqualone is indicated for the treatment of anxiety and sleep disorders. Launch Date1954 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4427217/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
METHAQUALONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
46.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4427217/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
METHAQUALONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
19 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4427217/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
METHAQUALONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
PubMed
Title | Date | PubMed |
---|---|---|
Extrapyramidal reaction in a patient on combined drug therapy: report of a case. | 1971 Jul-Aug |
|
Seven cases of somnambulism induced by drugs. | 1979 Jul |
|
Synthesis and anticonvulsant activity of some new 2-substituted 3-aryl-4(3H)-quinazolinones. | 1990 Jan |
|
A survey of reported synthesis of methaqualone and some positional and structural isomers. | 2001 Nov 1 |
|
Molecular epidemiology of multidrug-resistant tuberculosis, New York City, 1995-1997. | 2002 Nov |
|
A case of acute myeloid leukemia-M2 with trisomy 4 in addition to t(8;21). | 2008 Jan |
|
Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches. | 2009 Jan 10 |
|
A new recurring chromosome 13 abnormality in two older patients with de novo acute myeloid leukemia: An Indian experience. | 2009 Sep |
|
HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study. | 2010 Aug |
|
The Summary Index of Malaria Surveillance (SIMS): a stable index of malaria within India. | 2010 Feb 11 |
|
Semiautomatic quantification of angiogenesis. | 2010 Jul |
|
Retrospective cohort study of a new infant formula during the first 6 months of life: reflections on growth curves, human milk and formula feeding. | 2010 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/illicit/quaaludes.html
75-150 mg sedation. A commonly prescribed dose was 300 mg. Up to 600 mg was used for strong sedation.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26056160
Methaqualone displayed bell-shaped concentration-response curves as a positive allosteric modulator at all receptors when coapplied with GABA EC10 in concentrations ranging from 1 to 1000 uM (exemplified for a1b2g2S and a6b2delta. Pronounced rebound currents were observed at methaqualone concentrations of 300 uM and greater.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:55:16 GMT 2023
by
admin
on
Sat Dec 16 17:55:16 GMT 2023
|
Record UNII |
7ZKH8MQW6T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 862.3630
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
||
|
WHO-VATC |
QN05CX02
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
||
|
DEA NO. |
2565
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
||
|
NCI_THESAURUS |
C29756
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
||
|
WHO-ATC |
N05CM01
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
||
|
WHO-VATC |
QN05CM01
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
||
|
WHO-ATC |
N05CX02
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000081228
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
D008702
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
111388
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
m7302
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
3120
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
6821
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL282052
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
DB04833
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
631628
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
126877
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
1739
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
6823
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | RxNorm | ||
|
6292
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
7ZKH8MQW6T
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
966
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
METHAQUALONE
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
DTXSID7023279
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
SUB08840MIG
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
200-780-4
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
C640
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY | |||
|
72-44-6
Created by
admin on Sat Dec 16 17:55:17 GMT 2023 , Edited by admin on Sat Dec 16 17:55:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRECURSOR->PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PRECURSOR->PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|